Herpesvirus 4, Human

"Herpesvirus 4, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.

Descriptor ID	D004854
MeSH Number(s)	B04.280.210.400.500.450 B04.280.382.400.500.400 B04.613.204.500.500.400
Concept/Terms	Herpesvirus 4, Human Herpesvirus 4, Human Burkitt Lymphoma Virus Lymphoma Virus, Burkitt Burkitt's Lymphoma Virus Burkitts Lymphoma Virus E-B Virus E B Virus E-B Viruses Infectious Mononucleosis Virus Infectious Mononucleosis Viruses Mononucleosis Virus, Infectious Mononucleosis Viruses, Infectious Epstein-Barr Virus Epstein Barr Virus Herpesvirus 4 (gamma), Human HHV-4 Human Herpesvirus 4 Burkitt Herpesvirus Herpesvirus, Burkitt EBV

Below are MeSH descriptors whose meaning is more general than "Herpesvirus 4, Human".

Organisms [B]
Viruses [B04]
DNA Viruses [B04.280]
DNA Tumor Viruses [B04.280.210]
Gammaherpesvirinae [B04.280.210.400]
Lymphocryptovirus [B04.280.210.400.500]
Herpesvirus 4, Human [B04.280.210.400.500.450]
Herpesviridae [B04.280.382]
Gammaherpesvirinae [B04.280.382.400]
Lymphocryptovirus [B04.280.382.400.500]
Herpesvirus 4, Human [B04.280.382.400.500.400]
Oncogenic Viruses [B04.613]
DNA Tumor Viruses [B04.613.204]
Gammaherpesvirinae [B04.613.204.500]
Lymphocryptovirus [B04.613.204.500.500]
Herpesvirus 4, Human [B04.613.204.500.500.400]

Below are MeSH descriptors whose meaning is related to "Herpesvirus 4, Human".

Below are MeSH descriptors whose meaning is more specific than "Herpesvirus 4, Human".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Herpesvirus 4, Human" by people in this website by year, and whether "Herpesvirus 4, Human" was a major or minor topic of these publications.

Bar chart showing 69 publications over 25 distinct years, with a maximum of 7 publications in 2004 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	1	3
1997	1	0	1
1998	2	3	5
1999	1	0	1
2000	1	1	2
2002	1	2	3
2003	4	1	5
2004	5	2	7
2005	2	0	2
2006	2	2	4
2007	1	0	1
2009	1	0	1
2010	1	1	2
2011	1	1	2
2012	0	1	1
2013	1	0	1
2014	0	2	2
2016	2	2	4
2017	2	1	3
2018	0	1	1
2019	0	2	2
2020	1	2	3
2021	1	1	2
2022	1	3	4
2023	0	7	7

Below are the most recent publications written about "Herpesvirus 4, Human" by people in Profiles.

Miyoshi Y, Kise T, Morita K, Okada H, Imadome KI, Tsuchida N, Maeda A, Uchiyama Y, Kirino Y, Matsumoto N, Yokogawa N. Long-term remission of?VEXAS syndrome achieved by a single course of?CHOP therapy: A case report. Mod Rheumatol Case Rep. 2023 12 29; 8(1):199-204.

View in: PubMed
Manini N, Davidow K, Conard K, Powell J. Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-cell Lymphoma of Childhood. J Pediatr Hematol Oncol. 2024 03 01; 46(2):e208-e211.

View in: PubMed
Little JS, Dul?ry R, Shapiro RM, Aleissa MM, Prockop SE, Koreth J, Ritz J, Antin JH, Cutler C, Nikiforow S, Romee R, Issa NC, Ho VT, Baden LR, Soiffer RJ, Gooptu M. Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplant Cell Ther. 2024 02; 30(2):233.e1-233.e14.

View in: PubMed
Amengual JE, Pro B. How I treat posttransplant lymphoproliferative disorder. Blood. 2023 10 26; 142(17):1426-1437.

View in: PubMed
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023 10 24; 7(20):6339-6350.

View in: PubMed
Daher ND, Syed ZA. Bilateral interstitial keratitis following COVID-19: a case report. BMC Ophthalmol. 2023 Oct 13; 23(1):414.

View in: PubMed
Green EA, Hamaker NK, Lee KH. Comparison of vector elements and process conditions in transient and stable suspension HEK293 platforms using SARS-CoV-2 receptor binding domain as a model protein. BMC Biotechnol. 2023 03 07; 23(1):7.

View in: PubMed
Mitsuhashi S, Chalikonda D, Nazir B, Agarwal A, Coben R. Recurrent bleeding duodenal and colonic ulcers due to post-transplant lymphoproliferative disorder. Clin J Gastroenterol. 2023 Feb; 16(1):39-42.

View in: PubMed
Weiss SL, Zhang D, Farooqi S, Wallace DC. Sodium butyrate reverses lipopolysaccharide-induced mitochondrial dysfunction in lymphoblasts. J Cell Mol Med. 2022 06; 26(11):3290-3293.

View in: PubMed
Liu X, Guo L, Xie FY, Hu WH, Chen MY, He QM, Xu ZM, Zhang CQ, Peng YL, Tang LL, Mao YP, Sun R, Li JB, Argiris A, Hui EP, Sun Y, Ma J. Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):1063-1071.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement